Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days

Aptevo Therapeutics Inc.

First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.
Mipletamig (CD3 x CD123 bispecific) evaluated as frontline therapy in combination with venetoclax and azacitidine for AML.
Data builds on prior studies showing strong safety profile with manageable CRS below comparable treatment modalities.
RAINIER is designed for statistically defined efficacy analysis in newly diagnosed patients with limited options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.